CLL Screening Panel LPHCLL

A selection of haematology probes and a classical satellite probe for Chronic Lymphocytic Leukaemia

Chromosome 12 Enumeration probe

The product is a repeat sequence probe labelled in red which recognises the centromeric repeat sequence D12Z3. This product is also available in 5 (LPH028-S) and 10 (LPH028) test kit sizes and has been optimised for overnight hybridisation.

13q14.3

Deletions in 13q14 are observed in over 20% of B-cell CLL patients, and 64% of these deletions are believed to be the primary event in CLL. Patients with a 13q14.3 deletion have a better prognosis than patients with trisomy 12.

P53 (17p13.1)

P53 is a tumour suppressor gene that mediates the apoptosis of damaged cells. It has been found that approximately 17% of B-CLL patients have deletions of the TP53 gene. Patients exhibiting this genotype are associated with a poor prognosis as they harbour a proliferating population of damaged cells.

ATM (11q22.3)

The ATM gene is an important regulatory candidate in cell damage management, When it is deleted damaged cells are neither repaired nor apoptosed and are allowed to proliferate. The detection of the ATM deletion in CLL is important as it indicates poor prognosis and can define a patient’s therapy.

MYB (6q23.3)

The MYB gene is essential in hematopoietic cell proliferation and differentiation. It is located on chromosome 6q22 and is a 6q marker. Deletions of 6q occur in around 10% of cytogenetically abnormal patients and have been associated with the pathogenesis of CLL.